This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute lymphoblastic leukemia (ALL)	IκB kinase (IKK)	<p><i>In vitro</i> and mouse studies suggest that inhibiting IKK could help treat T cell ALL. In ALL cells with an activated <i>notch homolog 1 translocation-associated (NOTCH1)</i> oncogene, an IKK peptide inhibitor induced apoptosis compared with a control peptide. In a mouse model of Notch1-dependent leukemia, silencing Ikk led to greater cancer cell apoptosis and better survival than Ikk expression.</p> <p>Next steps include testing IKK inhibitors in additional models of leukemia.</p> <p>Myrex Inc.'s IKK inhibitor, MPI-0485520, is in preclinical testing to treat rheumatoid arthritis (RA) and cancer.</p> <p>Takeda Pharmaceutical Co. Ltd.'s IKK inhibitor, MLN0415, is in Phase I testing to treat inflammatory disease.</p> <p>SciBX 3(39); doi:10.1038/scibx.2010.1172 Published online Oct. 7, 2010</p>	Patent and licensing status unavailable	<p>Espinosa, L. <i>et al. Cancer Cell</i>; published online Sept. 14, 2010; doi:10.1016/j.ccr.2010.08.006</p> <p>Contact: Anna Bigas, Municipal Institute for Medical Research, Barcelona, Spain e-mail: abigas@imim.es</p> <p>Contact: Lluís Espinosa, same affiliation as above e-mail: lespinosa@imim.es</p> <p>Contact: Iannis Aifantis, New York University School of Medicine, New York, N.Y. e-mail: iannis.aifantis@nyumc.org</p>